A detailed history of Walleye Capital LLC transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Walleye Capital LLC holds 83,175 shares of PRLD stock, worth $108,127. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,175
Previous 15,229 446.16%
Holding current value
$108,127
Previous $58,000 196.55%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.07 - $6.37 $140,648 - $432,816
67,946 Added 446.16%
83,175 $172,000
Q2 2024

Aug 14, 2024

SELL
$3.32 - $5.63 $3,821 - $6,480
-1,151 Reduced 7.03%
15,229 $58,000
Q1 2024

May 15, 2024

BUY
$2.68 - $4.84 $43,898 - $79,279
16,380 New
16,380 $77,000
Q1 2022

May 16, 2022

SELL
$6.9 - $13.22 $289,482 - $554,631
-41,954 Closed
0 $0
Q4 2021

Mar 03, 2022

BUY
$11.89 - $31.74 $498,833 - $1.33 Million
41,954 New
41,954 $522,000

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $47.3M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.